Posted by admin on Jun 28th, 2022
Petco Health and Wellness (NASDAQ:WOOF – Get Rating) had its price target reduced by The Goldman Sachs Group from $23.00 to $21.00 in a report published on Monday, The Fly reports. The Goldman Sachs Group currently has a buy rating on the stock.
WOOF has been the topic of several other reports. UBS Group dropped their price objective on Petco Health and Wellness to $17.00 in a report on Wednesday, May 25th. Morgan Stanley began coverage on Petco Health and Wellness in a research note on Monday, May 16th. They issued an equal weight rating and a $21.00 price target on the stock. Wells Fargo & Company reaffirmed a buy rating and issued a $30.00 price target on shares of Petco Health and Wellness in a research note on Thursday, March 24th. Robert W. Baird lowered their price target on Petco Health and Wellness from $25.00 to $21.00 and set an outperform rating on the stock in a research note on Tuesday, May 24th. Finally, Wedbush lifted their price target on Petco Health and Wellness from $23.00 to $25.00 and gave the stock an outperform rating in a research note on Tuesday, March 29th. Two research analysts have rated the stock with a sell rating, four have issued a hold rating and eight have issued a buy rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of Hold and a consensus target price of $22.58.
Shares of WOOF stock opened at $16.49 on Monday. The company has a current ratio of 1.04, a quick ratio of 0.36 and a debt-to-equity ratio of 0.72. Petco Health and Wellness has a twelve month low of $13.71 and a twelve month high of $26.21. The stock has a 50 day moving average of $17.70 and a 200 day moving average of $18.61. The stock has a market cap of $3.75 billion, a P/E ratio of 24.25, a P/E/G ratio of 1.79 and a beta of 1.08.
Petco Health and Wellness (NASDAQ:WOOF – Get Rating) last issued its quarterly earnings data on Tuesday, May 24th. The company reported $0.17 EPS for the quarter, beating the consensus estimate of $0.15 by $0.02. Petco Health and Wellness had a return on equity of 8.93% and a net margin of 3.09%. The company had revenue of $1.48 billion for the quarter, compared to analyst estimates of $1.45 billion. During the same period last year, the company earned $0.17 earnings per share. Petco Health and Wellness’s quarterly revenue was up 4.3% compared to the same quarter last year. On average, research analysts predict that Petco Health and Wellness will post 0.87 earnings per share for the current fiscal year.
Hedge funds and other institutional investors have recently modified their holdings of the business. Moors & Cabot Inc. purchased a new stake in Petco Health and Wellness during the 3rd quarter worth about $25,000. MetLife Investment Management LLC purchased a new stake in Petco Health and Wellness during the 1st quarter worth about $25,000. Samalin Investment Counsel LLC increased its holdings in Petco Health and Wellness by 100.0% during the 4th quarter. Samalin Investment Counsel LLC now owns 2,000 shares of the company’s stock worth $40,000 after purchasing an additional 1,000 shares during the period. Chimera Capital Management LLC acquired a new position in shares of Petco Health and Wellness during the 4th quarter worth about $52,000. Finally, Future Financial Wealth Managment LLC acquired a new position in shares of Petco Health and Wellness during the 4th quarter worth about $70,000. Institutional investors own 62.52% of the company’s stock.
Petco Health and Wellness Company Profile (Get Rating)
Petco Health and Wellness Company, Inc, a health and wellness company, focuses on enhancing the lives of pets, pet parents, and its Petco partners. The company provides veterinary care, grooming, training, tele-health, and Vital Care and pet health insurance services, as well as veterinary services through Vetco mobile clinics.
Receive News & Ratings for Petco Health and Wellness Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Petco Health and Wellness and related companies with MarketBeat.com’s FREE daily email newsletter.
GMS (NYSE:GMS) Upgraded by StockNews.com to “Strong-Buy”
Wedbush Lowers Epizyme (NASDAQ:EPZM) to Neutral